As­traZeneca inks a car­dio drug de­vel­op­ment pact with mR­NA spe­cial­ist Mod­er­na

As­traZeneca has come back to the ta­ble to ink a new col­lab­o­ra­tion deal with the mes­sen­ger RNA biotech Mod­er­na.

Al­ready a sig­nif­i­cant part­ner and in­vestor in the uni­corn biotech, As­traZeneca struck a deal to set up a pro­gram with Mod­er­na on re­lax­in, look­ing to coax cells in­to pro­duc­ing a pro­tein that could have a ton­ic ef­fect on heart dis­ease.

That’s a tall or­der, as car­dio re­mains one of the tough­est and most de­mand­ing fields in bio­phar­ma. Back in March No­var­tis was forced to con­cede that its big Phase III for sere­lax­in —  a re­com­bi­nant form of the re­lax­in-2 hor­mone — failed a big Phase III.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.